Gene:
NPM1
nucleophosmin (nucleolar phosphoprotein B23, numatrin)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  nucleolar phosphoprotein B23; nucleophosmin/nucleoplasmin family, member 1; numatrin
Alternate Symbols:  B23; NPM
PharmGKB Accession Id: PA31712

Details

Cytogenetic Location: chr5 : q35.1 - q35.1
GP mRNA Boundary: chr5 : 170814708 - 170837888
GP Gene Boundary: chr5 : 170804708 - 170840888
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Aurora B signaling - (Pathway Interaction Database NCI-Nature Curated)
  2. BARD1 signaling events - (Pathway Interaction Database NCI-Nature Curated)
  3. HIF-1-alpha transcription factor network - (Pathway Interaction Database NCI-Nature Curated)

Publications related to NPM1: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. The pharmacogenomics journal. 2010. Gréen H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009. Roumier Christophe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Recurring mutations found by sequencing an acute myeloid leukemia genome. The New England journal of medicine. 2009. Mardis Elaine R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009. Zhao Dan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009. Hartford Christine M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England journal of medicine. 2008. Schlenk Richard F, et al. PubMed

LinkOuts

UniProtKB:
NPM_HUMAN (P06748)
Q9BYG9_HUMAN (Q9BYG9)
Ensembl:
ENSG00000181163
GenAtlas:
NPM1
GeneCard:
NPM1
MutDB:
NPM1
ALFRED:
LO159835F
HuGE:
NPM1
Comparative Toxicogenomics Database:
4869
ModBase:
Q96EA5
HumanCyc Gene:
HS11583
HGNC:
7910

Common Searches